| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
AT-101 [(R)-(-)-Gossypol acetic acid, the levorotatory isomer of a natural product Gossypol], is a novel, oral and potent inhibitor of Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; it shows no inhibition against BIR3 and BID. Gossypol's R-(-) enantiomer, AT-101, has potential antineoplastic activity and is orally bioavailable. R-(-)-gossypol functions as a BH3 mimetic, attaching to the hydrophobic surface binding groove BH3 of the anti-apoptotic proteins Bcl-2 and Bcl-xL and preventing them from heterodimerizing with pro-apoptotic Bcl-2 family members like Bad, Bid, and Bim. This may stop tumor cell growth and trigger apoptosis in tumor cells. A polyphenolic substance called racemic gossypol was discovered in cottonseed.
| Targets |
Mcl-1 (Ki=170 nM); Bcl-2 (Ki=260 nM); Bcl-xL (Ki=480 nM); Autophagy
|
|---|---|
| ln Vitro |
The (+)-Gossypol and (R)-(-)-Gossypol enantiomers are the two forms of the naturally occurring racemic Gossypol. Gossypol (AT-101) and (+) are in (R)-(-) AT-101 is more effective than (+)-Gossypol in inhibiting cell growth and inducing apoptosis, possibly as a result of the influence of serum in the cell culture experiments. Although both AT-101 and (+)-Gossypol bind to Bcl-2 or Bcl-xL with similar binding affinities. In 6-day MTT assays, Gossypol's racemic form and each of its enantiomers are evaluated against UM-SCC-6 and UM-SCC-14A. The (+)-Gossypol and (R)-(-)-Gossypol enantiomers are the two forms of the naturally occurring racemic Gossypol. Gossypol (AT-101) and (+) are in (R)-(-) AT-101 is more effective than (+)-Gossypol in inhibiting cell growth and inducing apoptosis, possibly as a result of the influence of serum in the cell culture experiments. Although both AT-101 and (+)-Gossypol bind to Bcl-2 or Bcl-xL with similar binding affinities. In 6-day MTT assays, Gossypol's racemic form and each of its enantiomers are evaluated against UM-SCC-6 and UM-SCC-14A. Human fibroblast cell line growth was 50% inhibited by AT-101 doses that were 2- to 10-fold higher than those needed for HNSCC cell line growth. (R)-(-)-Gossypol (AT-101) concentrations are 2- to 3-fold higher than for HNSCC cell lines to inhibit human oral keratinocyte growth by 50%. In ten UM-SCC cell lines in a 6-day MTT assay, (R)-(-)-Gossypol (AT-101) inhibits cell growth in a dose-dependent manner over a range of 0.5 to 10 M. A very sensitive group of cell lines have an IC50 of 2–5 M, while a less sensitive group have IC50 clusters around 10 M[1]. The Bcl-2, Mcl-1, and Bcl-xL proteins bind to (R)-(-)-Gossypol (AT-101) with Ki values of 260–30 nM, 170–10 nM, and 480–40 nM, respectively[2].
|
| Enzyme Assay |
For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
|
| Cell Assay |
Two representative UM-SCC cell lines, UM-SCC-6 and UM-SCC-14A, are continuously exposed to 0 (vehicle control), 5 or 10 μM (±)-Gossypol, (R)-(-)-Gossypol or (+)-Gossypol in a 6-day MTT cell survival assay.
|
| Animal Protocol |
~40 mg/kg
Administered via i.v. or i.p. Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts |
| References |
|
| Molecular Formula |
C30H30O8.C2H4O2
|
|
|---|---|---|
| Molecular Weight |
578.61
|
|
| Exact Mass |
578.2152
|
|
| Elemental Analysis |
C, 66.43; H, 5.92; O, 27.65
|
|
| CAS # |
866541-93-7
|
|
| Related CAS # |
(S)-Gossypol (acetic acid);1189561-66-7;Gossypol (acetic acid);12542-36-8;(R)-(-)-Gossypol;90141-22-3
|
|
| Appearance |
Solid powder
|
|
| SMILES |
O=CC1=C(O)C(O)=C(C(C)C)C2=CC(C)=[C@@]([C@@]3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O)C(O)=C12.CC(O)=O
|
|
| InChi Key |
NIOHNDKHQHVLKA-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)
|
|
| Chemical Name |
acetic acid compound with (S)-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1:1)
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7283 mL | 8.6414 mL | 17.2828 mL | |
| 5 mM | 0.3457 mL | 1.7283 mL | 3.4566 mL | |
| 10 mM | 0.1728 mL | 0.8641 mL | 1.7283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05338931 | Recruiting | Drug: AT101 | B-cell Non Hodgkin Lymphoma | AbClon | March 15, 2022 | Phase 1 Phase 2 |
| NCT02697344 | Active Recruiting |
Drug: Dexamethasone Drug: Lenalidomide |
Recurrent Plasma Cell Myeloma | Mayo Clinic | April 14, 2016 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA